Tangent Reprofiling - Combination therapies for hormone-dependent cancers. Utilising an innovative therapeutic strategy of drugs and nutritional supplements. Treating Prostate (and Ovarian, Breast and Endometrial) cancers beyond castration resistance.

一些癌症肿瘤需要或在雌激素或睾酮等类固醇激素存在的情况下生长得更快。这些癌症可以通过化疗药物来治疗，以利用体内自然存在的荷尔蒙来预防肿瘤。这些药物中的许多都是通过阻断肿瘤外边缘的激素受体来发挥作用的，通过阻止肿瘤识别激素来饥饿肿瘤。然而，许多激素依赖型肿瘤通过学习在体内制造激素而对这些药物产生抗药性。我们使用我们的专利技术来研究目前用于非癌症疾病的药物。一种药物被确认能够防止肿瘤产生内分泌激素。这种药物已经在临床上用于一种需要长期使用的替代疾病，因此其安全性和副作用已经在广泛的患者群体中得到了很好的表征。我们建议将这种药物与目前的化疗方案相结合，从内部攻击肿瘤，同时维持上述饥饿过程。我们已经有数据表明，在体外，使用该药物可以减少前列腺癌细胞的生长，然而，我们现在需要扩大这一点，以寻找其他药物组合；寻找其他癌细胞类型；并在动物模型中测试最终的药物组合。除了将我们的药物与当前的化疗相结合，我们还将与omega-3脂肪酸结合进行测试。这些都是很受欢迎的营养补充剂，并被认为对某些癌症有治疗效果。这种补充剂应该与我们的药物协同工作，以提供额外的好处。Omega-3脂肪酸有几种形式，所以我们需要确定最佳的，然后寻找我们的药物和补充剂的理想比例。我们相信这提供了一个令人兴奋的机会，延长一系列常见癌症的成功治疗，包括前列腺癌、子宫内膜癌、乳腺癌和卵巢癌。

Some cancerous tumors require, or grow faster in the presence of, steroid hormones such as estrogen or testosterone. These cancers can be treated by chemotherapy drugs to prevent the tumor using hormones found naturally in the body. Many of these drugs work by blocking the receptors for the hormone on the outside edges of the tumor, starving the tumor by preventing it from recognizing the hormone. However, many hormone-dependant tumors develop resistance to these drugs by learning to make the hormones internally.We used our proprietary technology to study drugs that are currently used in non-cancerdiseases. One drug was identified as being capable of preventing internal hormone production by tumors. This drug is already in clinical use for an alternative disease which requires long term use, so the safety and side effects are already well characterized across a broad population of patients. We propose combining this drug with current chemotherapy regimes to attack the tumor from within while maintaining the starvation procedure described above.We already have data to demonstrate a reduction in growth of prostate cancer cells with the drug in vitro, however, we now need to expand this to look at additional combinations of drugs; to look at additional cancer cell types; and to test the final drug combinations in animal models.As well as combining our drug with current chemotherapies, we will test it in combination with omega-3 fatty acids. These are popular nutritional supplements, and have been proposed to have therapeutic effect in some cancers. This supplement should work in concert with our drug to provide additional benefit. There are several forms of omega-3 fatty acids, so we need to identify the best and then look for the ideal ratio of our drug and the supplement.We believe this offers an exciting opportunity to prolong successful treatment of a range of common cancers including prostate, endometrial, breast and ovarian cancer.